Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/46045
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSandhu, Geeta-
dc.contributor.authorGordon, Evangeline Armstrong-
dc.contributor.authorAdattini, Josephine-
dc.contributor.authorO'Neill, Niamh-
dc.contributor.authorChambers, Pinkie-
dc.contributor.authorJohnson, David W.-
dc.contributor.authorKelly, Aisling-
dc.contributor.authorLiauw, Winston-
dc.contributor.authorMallett, Andrew J.-
dc.contributor.authorMichael, Michael-
dc.contributor.authorMirkov, Sanja-
dc.contributor.authorScuderi, Carla-
dc.contributor.authorShingleton, Julia-
dc.contributor.authorSiderov, Jim-
dc.contributor.authorSPRANGERS, Ben-
dc.contributor.authorStein, Brian N.-
dc.contributor.authorTunnicliffe, David J.-
dc.contributor.authorWard, Robyn L.-
dc.date.accessioned2025-05-20T13:54:15Z-
dc.date.available2025-05-20T13:54:15Z-
dc.date.issued2025-
dc.date.submitted2025-05-16T11:05:14Z-
dc.identifier.citationEClinicalMedicine, 82 (Art N° 103101)-
dc.identifier.urihttp://hdl.handle.net/1942/46045-
dc.description.abstractReduced kidney function (or kidney dysfunction) is commonly an exclusion criterion for randomised controlled trials (RCTs) in cancer. Consequently, high quality evidence for anticancer drug dosing in reduced kidney function is limited and no internationally agreed guidelines exist to inform prescribing decisions in this population. A methodology for guideline development was applied which did not require availability of RCTs but used critical appraisal of existing observational literature and group consensus. An international multidisciplinary working group (n = 38) established consensus recommendations in two parts to form the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD). The approach enabled virtual participation worldwide. In Part 1 we developed a standardised approach for assessment and classification of kidney function in patients with cancer using global nephrology standards and working group expertise. Part 2 involved a comprehensive literature search of 59 anticancer drugs followed by a critical appraisal of the evidence certainty through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process and development of dosing recommendations in reduced kidney function. Key external stakeholders (n =9) invited expert contributors (n = 25), and the working group participated in virtual interactive workshops to vote on the acceptability of these recommendations. The participants were provided with evaluation of the literature, and they engaged in several rounds of virtual discussion (involving robustness of the evidence behind recommendations and their real-world application) and anonymous consensus voting. Adapting the ADDIKD guideline development process to a virtual format enabled engagement with a very broad base of specialised international experts especially during the global pandemic. Combining GRADE meth odology with consensus-building approaches was an effective method of producing recommendations (in an area lacking RCTs) by merging critical review of the literature with expert opinion and clinical practice. Copyright (c) 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.description.sponsorshipDevelopment of the ADDIKD guideline is funded by the Cancer Institute NSW as part of the NSW Government and received no funding from external commercial sources.-
dc.language.isoen-
dc.publisherELSEVIER-
dc.rights2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.subject.otherChemotherapy-
dc.subject.otherDrug dosing-
dc.subject.otherKidney dysfunction-
dc.subject.otherRenal-
dc.subject.otherOncology-
dc.subject.otherHaematology-
dc.subject.otherPharmacokinetics-
dc.titleA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function-
dc.typeJournal Contribution-
dc.identifier.volume82-
local.format.pages12-
local.bibliographicCitation.jcatA1-
dc.description.notesSandhu, G (corresponding author), St Vincents Hosp, Pharm Dept, Sydney, NSW, Australia.-
dc.description.notesgeetpal.sandhu@svha.org.au-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnr103101-
dc.identifier.doi10.1016/j.eclinm.2025.103101-
dc.identifier.pmid40290846-
dc.identifier.isi001478631200001-
dc.contributor.orcidMirkov, Sanja/0000-0003-1533-0531-
local.provider.typewosris-
local.description.affiliation[Sandhu, Geeta; Ward, Robyn L.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.-
local.description.affiliation[Sandhu, Geeta; Gordon, Evangeline Armstrong; Adattini, Josephine; O'Neill, Niamh; Kelly, Aisling; Shingleton, Julia; Ward, Robyn L.] eviQ, Canc Inst NSW, St Leonards, NSW, Australia.-
local.description.affiliation[Sandhu, Geeta] St Vincents Hosp, Pharm Dept, Sydney, NSW, Australia.-
local.description.affiliation[Chambers, Pinkie] UCL, Sch Pharm, London, England.-
local.description.affiliation[Chambers, Pinkie] Univ Coll London Hosp, Univ Coll London Ctr Med Optimisat Res & Educ, London, England.-
local.description.affiliation[Johnson, David W.] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia.-
local.description.affiliation[Johnson, David W.] Princess Alexandra Hosp, Dept Kidney & Transplant Serv, Brisbane, Qld, Australia.-
local.description.affiliation[Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia.-
local.description.affiliation[Liauw, Winston] St George Hosp, Canc Care Ctr, Kogarah, NSW, Australia.-
local.description.affiliation[Liauw, Winston] Univ New South Wales, Sch Clin Med, Sydney, NSW, Australia.-
local.description.affiliation[Mallett, Andrew J.] Townsville Univ Hosp, Dept Renal Med, Townsville, Qld, Australia.-
local.description.affiliation[Mallett, Andrew J.] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia.-
local.description.affiliation[Mallett, Andrew J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.-
local.description.affiliation[Michael, Michael] Peter Maallum Canc Ctr, Parkville, Vic, Australia.-
local.description.affiliation[Michael, Michael] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.-
local.description.affiliation[Mirkov, Sanja] Cairns & Hinterland Hosp & Hlth Serv, Pharm Dept, Cairns, Qld 4870, Australia.-
local.description.affiliation[Scuderi, Carla] Metro North Hosp & Hlth Serv, Kidney Hlth Serv, Brisbane, Qld, Australia.-
local.description.affiliation[Scuderi, Carla] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia.-
local.description.affiliation[Siderov, Jim] Austin Hlth, Pharm Dept, Melbourne, Vic, Australia.-
local.description.affiliation[Sprangers, Ben] Ziekenhuis Oost Limburg, Div Nephrol, Genk, Belgium.-
local.description.affiliation[Sprangers, Ben] UHasselt, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium.-
local.description.affiliation[Stein, Brian N.] ICON Canc Ctr, Adelaide, SA, Australia.-
local.description.affiliation[Stein, Brian N.] Univ Adelaide, Adelaide, SA, Australia.-
local.description.affiliation[Tunnicliffe, David J.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.-
local.description.affiliation[Tunnicliffe, David J.] Childrens Hosp Westmead, Ctr Kidney Res, Westmead, NSW, Australia.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorSandhu, Geeta-
item.contributorGordon, Evangeline Armstrong-
item.contributorAdattini, Josephine-
item.contributorO'Neill, Niamh-
item.contributorChambers, Pinkie-
item.contributorJohnson, David W.-
item.contributorKelly, Aisling-
item.contributorLiauw, Winston-
item.contributorMallett, Andrew J.-
item.contributorMichael, Michael-
item.contributorMirkov, Sanja-
item.contributorScuderi, Carla-
item.contributorShingleton, Julia-
item.contributorSiderov, Jim-
item.contributorSPRANGERS, Ben-
item.contributorStein, Brian N.-
item.contributorTunnicliffe, David J.-
item.contributorWard, Robyn L.-
item.fullcitationSandhu, Geeta; Gordon, Evangeline Armstrong; Adattini, Josephine; O'Neill, Niamh; Chambers, Pinkie; Johnson, David W.; Kelly, Aisling; Liauw, Winston; Mallett, Andrew J.; Michael, Michael; Mirkov, Sanja; Scuderi, Carla; Shingleton, Julia; Siderov, Jim; SPRANGERS, Ben; Stein, Brian N.; Tunnicliffe, David J. & Ward, Robyn L. (2025) A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function. In: EClinicalMedicine, 82 (Art N° 103101).-
item.accessRightsOpen Access-
crisitem.journal.eissn2589-5370-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function.pdfPublished version587.01 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.